1
|
Crawford KS, Volkman BF. Prospects for targeting ACKR1 in cancer and other diseases. Front Immunol 2023; 14:1111960. [PMID: 37006247 PMCID: PMC10050359 DOI: 10.3389/fimmu.2023.1111960] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Accepted: 03/03/2023] [Indexed: 03/17/2023] Open
Abstract
The chemokine network is comprised of a family of signal proteins that encode messages for cells displaying chemokine G-protein coupled receptors (GPCRs). The diversity of effects on cellular functions, particularly directed migration of different cell types to sites of inflammation, is enabled by different combinations of chemokines activating signal transduction cascades on cells displaying a combination of receptors. These signals can contribute to autoimmune disease or be hijacked in cancer to stimulate cancer progression and metastatic migration. Thus far, three chemokine receptor-targeting drugs have been approved for clinical use: Maraviroc for HIV, Plerixafor for hematopoietic stem cell mobilization, and Mogalizumab for cutaneous T-cell lymphoma. Numerous compounds have been developed to inhibit specific chemokine GPCRs, but the complexity of the chemokine network has precluded more widespread clinical implementation, particularly as anti-neoplastic and anti-metastatic agents. Drugs that block a single signaling axis may be rendered ineffective or cause adverse reactions because each chemokine and receptor often have multiple context-specific functions. The chemokine network is tightly regulated at multiple levels, including by atypical chemokine receptors (ACKRs) that control chemokine gradients independently of G-proteins. ACKRs have numerous functions linked to chemokine immobilization, movement through and within cells, and recruitment of alternate effectors like β-arrestins. Atypical chemokine receptor 1 (ACKR1), previously known as the Duffy antigen receptor for chemokines (DARC), is a key regulator that binds chemokines involved in inflammatory responses and cancer proliferation, angiogenesis, and metastasis. Understanding more about ACKR1 in different diseases and populations may contribute to the development of therapeutic strategies targeting the chemokine network.
Collapse
Affiliation(s)
- Kyler S. Crawford
- Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, United States
| | | |
Collapse
|
2
|
Elhadad D, Simon AJ, Bronstein Y, Yana M, Sharon N. Presence of "ACKR1/DARC null" polymorphism in Arabs from Jisr az-Zarqa with benign ethnic neutropenia. Pediatr Res 2022; 91:1012-1014. [PMID: 34175890 DOI: 10.1038/s41390-021-01623-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/02/2021] [Revised: 06/02/2021] [Accepted: 06/03/2021] [Indexed: 11/09/2022]
Affiliation(s)
- Dana Elhadad
- Division of Pediatric Hematology-Oncology Laniado Medical Center, Netanya, Israel.
| | - Amos J Simon
- Pediatric Department A and the Immunology Service, Jeffrey Modell Foundation Center, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Yotam Bronstein
- Division of Pediatric Hematology-Oncology Laniado Medical Center, Netanya, Israel
| | - Moshe Yana
- Division of Pediatric Hematology-Oncology Laniado Medical Center, Netanya, Israel
| | - Nechama Sharon
- Division of Pediatric Hematology-Oncology Laniado Medical Center, Netanya, Israel
| |
Collapse
|
3
|
Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Cancers (Basel) 2021; 13:cancers13225607. [PMID: 34830762 PMCID: PMC8616108 DOI: 10.3390/cancers13225607] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2021] [Revised: 11/02/2021] [Accepted: 11/06/2021] [Indexed: 12/12/2022] Open
Abstract
Simple Summary Myelosuppression is a side effect of chemotherapy, in which the production of red and white blood cells and platelets is reduced, increasing risk of infections. Blinatumomab, a bispecific T-cell engager (BiTE®) molecule, is a novel anticancer drug that kills acute lymphoblastic leukemia (ALL) cells while sparing majority of the normal bone marrow cells. Results from our study, which compared the effects of blinatumomab treatment with chemotherapy on bone marrow function in a large number of patients with ALL, indicated that the decrease in blood cell counts was more severe and lasted longer after chemotherapy compared with blinatumomab treatment, in which the effects were transient. Survival in patients treated with blinatumomab achieving complete remission was more similar between those with incomplete recovery of blood cell counts versus those with complete blood cell counts than the corresponding survival outcomes seen with chemotherapy. In conclusion, blinatumomab treatment caused transient myelosuppression when compared with chemotherapy. Abstract Association of blinatumomab treatment with myelosuppression was examined in this study. Peripheral blood counts were assessed prior to, during, and after blinatumomab treatment in patients with relapsed/refractory Philadelphia chromosome-negative (Ph−) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL; n = 267) and Ph+ BCP-ALL (n = 45) from the TOWER and ALCANTARA studies, respectively, or chemotherapy in patients with Ph− BCP-ALL (n = 109) from the TOWER study; all the patients with relapsed/refractory BCP-ALL and responders achieving complete remission (CR) or CR with partial/incomplete hematological recovery (CRh/CRi) were evaluated. Event-free survival (EFS) and overall survival (OS) were assessed in patients achieving CR and CRh/CRi. Median leukocyte, neutrophil, and platelet counts increased during two blinatumomab cycles but remained low longer after chemotherapy. Among the responders, there was a trend that a greater proportion of patients achieved CR with blinatumomab (Ph−, 76.5%; Ph+, 77.8%) versus with chemotherapy (Ph−, 63.6%). In the TOWER study, the survival prognosis for patients achieving CRh/CRi versus CR with blinatumomab was more similar (median OS, 11.9 (95% CI, 3.9–not estimable (NE)) vs. 15.0 (95% CI, 10.4–NE) months, p = 0.062) than with chemotherapy (5.2 (95% CI, 1.6–NE) vs. 18.9 (95% CI, 9.3–NE) months, p = 0.013). Blinatumomab treatment, with only temporary and transient myelosuppression, resulted in a greater survival benefit than chemotherapy.
Collapse
|
4
|
Cassidy T, Humphries AR, Craig M, Mackey MC. Characterizing Chemotherapy-Induced Neutropenia and Monocytopenia Through Mathematical Modelling. Bull Math Biol 2020; 82:104. [PMID: 32737602 DOI: 10.1007/s11538-020-00777-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2020] [Accepted: 07/11/2020] [Indexed: 12/18/2022]
Abstract
In spite of the recent focus on the development of novel targeted drugs to treat cancer, cytotoxic chemotherapy remains the standard treatment for the vast majority of patients. Unfortunately, chemotherapy is associated with high hematopoietic toxicity that may limit its efficacy. We have previously established potential strategies to mitigate chemotherapy-induced neutropenia (a lack of circulating neutrophils) using a mechanistic model of granulopoiesis to predict the interactions defining the neutrophil response to chemotherapy and to define optimal strategies for concurrent chemotherapy/prophylactic granulocyte colony-stimulating factor (G-CSF). Here, we extend our analyses to include monocyte production by constructing and parameterizing a model of monocytopoiesis. Using data for neutrophil and monocyte concentrations during chemotherapy in a large cohort of childhood acute lymphoblastic leukemia patients, we leveraged our model to determine the relationship between the monocyte and neutrophil nadirs during cyclic chemotherapy. We show that monocytopenia precedes neutropenia by 3 days, and rationalize the use of G-CSF during chemotherapy by establishing that the onset of monocytopenia can be used as a clinical marker for G-CSF dosing post-chemotherapy. This work therefore has important clinical applications as a comprehensive approach to understanding the relationship between monocyte and neutrophils after cyclic chemotherapy with or without G-CSF support.
Collapse
Affiliation(s)
- Tyler Cassidy
- Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM, 87545, USA
| | - Antony R Humphries
- Department of Mathematics and Statistics, McGill University, Montréal, QC, H3A 0B9, Canada.,Department of Physiology, McGill University, Montréal, QC, H3A 0B9, Canada
| | - Morgan Craig
- Department of Mathematics and Statistics, Université de Montréal, Montréal, Canada. .,CHU Sainte-Justine Research Centre, University of Montreal, Montréal, Canada.
| | - Michael C Mackey
- Department of Physiology, McGill University, 3655 Drummond, Montréal, QC, H3G 1Y6, Canada.,Department of Mathematics and Statistics, McGill University, 3655 Drummond, Montréal, QC, H3G 1Y6, Canada.,Department of Physics, McGill University, 3655 Drummond, Montréal, QC, H3G 1Y6, Canada
| |
Collapse
|
5
|
Mackey MC, Glisovic S, Leclerc JM, Pastore Y, Krajinovic M, Craig M. The timing of cyclic cytotoxic chemotherapy can worsen neutropenia and neutrophilia. Br J Clin Pharmacol 2020; 87:687-693. [PMID: 32533708 DOI: 10.1111/bcp.14424] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2020] [Revised: 05/17/2020] [Accepted: 05/28/2020] [Indexed: 01/16/2023] Open
Abstract
Despite recent advances in immunotherapies, cytotoxic chemotherapy continues to be a first-line treatment option for the majority of cancers. Unfortunately, a common side effect in patients undergoing chemotherapy treatment is neutropenia. To mitigate the risk of neutropenia and febrile neutropenia, prophylactic treatment with granulocyte-colony stimulating factor (G-CSF) is administered. Extensive pharmacokinetic/pharmacodynamic modelling of myelosuppression during chemotherapy has suggested avenues for therapy optimization to mitigate this neutropenia. However, the issue of resonance, whereby neutrophil oscillations are induced by the periodic administration of cytotoxic chemotherapy and the coadministration of G-CSF, potentially aggravating a patient's neutropenic/neutrophilic status, is not well-characterized in the clinical literature. Here, through analysis of neutrophil data from young acute lymphoblastic leukaemia patients, we find that resonance is occurring during cyclic chemotherapy treatment in 26% of these patients. Motivated by these data and our previous modelling studies on adult lymphoma patients, we examined resonance during treatment with or without G-CSF. Using our quantitative systems pharmacology model of granulopoiesis, we show that the timing of cyclic chemotherapy can worsen neutropenia or neutrophilia, and suggest clinically-actionable schedules to reduce the resonant effect. We emphasize that delaying supportive G-CSF therapy to 6-7 days after chemotherapy can mitigate myelosuppressive effects. This study therefore highlights the importance of quantitative systems pharmacology for the clinical practice for developing rational therapeutic strategies.
Collapse
Affiliation(s)
| | | | - Jean-Marie Leclerc
- CHU Sainte-Justine Research Centre, Montreal, Canada.,Department of Pediatrics, University of Montreal, Montreal, Canada
| | - Yves Pastore
- CHU Sainte-Justine Research Centre, Montreal, Canada.,Department of Pediatrics, University of Montreal, Montreal, Canada
| | - Maja Krajinovic
- CHU Sainte-Justine Research Centre, Montreal, Canada.,Department of Pharmacology and Physiology, University of Montreal, Montreal, Canada
| | - Morgan Craig
- Department of Physiology, McGill University, Montreal, Canada.,CHU Sainte-Justine Research Centre, Montreal, Canada.,Department of Mathematics and Statistics, University of Montreal, Montreal, Canada
| |
Collapse
|
6
|
Gatineau-Sailliant S, Glisovic S, Gagné V, Laverdière C, Leclerc JM, Silverman L, Sinnett D, Krajinovic M, Pastore Y. Impact of DARC, GSDMA and CXCL2 polymorphisms on induction toxicity in children with acute lymphoblastic leukemia: A complementary study. Leuk Res 2019; 86:106228. [DOI: 10.1016/j.leukres.2019.106228] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Revised: 09/18/2019] [Accepted: 09/25/2019] [Indexed: 10/25/2022]
|
7
|
de Andrade Bernal Fagiani M, Fluminhan A, de Azevedo Mello F, Yabuki D, Gonçalves GV, Tsujigushi LK, Pereira LG, da Silva KA, da Silva SBB, Santarem CL, Giozo PFI, de Souza Reis LSL. l-arginine minimizes immunosuppression and prothrombin time and enhances the genotoxicity of 5-fluorouracil in rats. Nutrition 2019; 66:94-100. [PMID: 31252338 DOI: 10.1016/j.nut.2019.04.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Revised: 03/31/2019] [Accepted: 04/24/2019] [Indexed: 01/26/2023]
Abstract
OBJECTIVE The aim of this study was to evaluate the effect of low doses of l-arginine supplementation on hemogram, integrity of DNA and spleen, inflammatory infiltrate in the jejunum, and in the coagulogram of rats submitted to 5-fluorouracil (5-FU) chemotherapy. METHODS Thirty-two Wistar rats were fed commercial feed and water ad libitum and grouped into four (eight rats per group): The control group was given a 0.9% physiologic solution to simulate the application of 5-FU in the other groups; the G5-FU group was given a dose of 5-FU; the GArg50 and GArg100 groups were given a dose of 5-FU and supplemented with 50 and 100 mg l-arginine/d added in the drinking water ad libitum. RESULTS The rats in the GArg50 group did not lose weight after chemotherapy. GArg50 rats presented polycythemia owing to dehydration caused by diarrhea generated by 5-FU. GArg100 rats had increased total leukocyte count, eosinophils, lymphocytes, and index in the total index of DNA damage, yet showed a reduction in prothrombin time and in the spleen depletion index. Rats in the G5-FU, GArg50, and GArg100 groups had similar moderate inflammatory infiltrate in the jejunum. CONCLUSION Supplementation with 100 mg/d of l-arginine minimized immunosuppression, spleen depletion, and prothrombin time and contributed to the breakdown of 5-FU-generated DNA in Wistar rats. Supplementation with 50 mg/d of l-arginine decreased the weight loss generated by 5-FU in Wistar rats. Supplements with 50 or 100 mg of l-arginine did not interfere with 5-FU-generated jejunal inflammatory infiltrate.
Collapse
Affiliation(s)
| | - Antônio Fluminhan
- State University of Sao Paulo (UNESP), College of Sciences and Technology (FCT), Presidente Prudente, Sao Paulo, Brasil
| | - Fabíola de Azevedo Mello
- Postgraduate Program in Animal Science, Universidade do Oeste Paulista, Presidente Prudente, Sao Paulo, Brasil
| | - Denise Yabuki
- Graduation in Veterinary Medicine, Universidade do Oeste Paulista, Presidente Prudente, Sao Paulo, Brazil
| | | | | | - Liliane Girotto Pereira
- Postgraduate Program in Animal Science, Universidade do Oeste Paulista, Presidente Prudente, Sao Paulo, Brasil
| | - Kesia Araújo da Silva
- Graduation in Veterinary Medicine, Universidade do Oeste Paulista, Presidente Prudente, Sao Paulo, Brazil
| | | | - Cecilia Laposy Santarem
- Postgraduate Program in Animal Science, Universidade do Oeste Paulista, Presidente Prudente, Sao Paulo, Brasil; Graduation in Veterinary Medicine, Universidade do Oeste Paulista, Presidente Prudente, Sao Paulo, Brazil
| | - Paulo Felipe Izique Giozo
- Postgraduate Program in Animal Science, Universidade do Oeste Paulista, Presidente Prudente, Sao Paulo, Brasil; Graduation in Veterinary Medicine, Universidade do Oeste Paulista, Presidente Prudente, Sao Paulo, Brazil
| | - Luis Souza Lima de Souza Reis
- Postgraduate Program in Animal Science, Universidade do Oeste Paulista, Presidente Prudente, Sao Paulo, Brasil; Graduation in Veterinary Medicine, Universidade do Oeste Paulista, Presidente Prudente, Sao Paulo, Brazil
| |
Collapse
|
8
|
Rappoport N, Simon AJ, Amariglio N, Rechavi G. The Duffy antigen receptor for chemokines, ACKR1,- 'Jeanne DARC' of benign neutropenia. Br J Haematol 2018; 184:497-507. [PMID: 30592023 DOI: 10.1111/bjh.15730] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Benign neutropenia, observed in different ethnic groups, is the most common form of neutropenia worldwide. A specific single nucleotide polymorphism, rs2814778, located at the promoter of the ACKR1 (previously termed DARC) gene, which disrupts a binding site for the GATA1 erythroid transcription factor, resulting in a ACKR1-null phenotype, was found to serve as a predictor of low white blood cell and neutrophil counts in African-Americans and Yemenite Jews. Individuals with benign neutropenia due to the ACKR1-null allele have been found to have an increased susceptibility to human immunodeficiency virus infection and, on the other hand, a protective effect against malaria. The associated protective effect may explain the spread of the ACKR1-null allele by natural selection. The reviewed relationships between ACKR1 polymorphism and various pathological states may have important clinical implications to individuals with and without benign neutropenia. Potential mechanisms for ACKR1 (previously termed DARC) modulation during neutrophil recruitment to inflammation, and chemokine bioavailability in the circulation and in local tissue are reviewed and discussed.
Collapse
Affiliation(s)
- Naama Rappoport
- Cancer Research Centre, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Amos J Simon
- Cancer Research Centre, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Institute of Haematology, Sheba Medical Centre, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Ninette Amariglio
- Cancer Research Centre, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Institute of Haematology, Sheba Medical Centre, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Mina and Everard Goodman Faculty of Life Sciences, Bar Ilan University, Ramat-Gan, Israel
| | - Gideon Rechavi
- Cancer Research Centre, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|